Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -16.62 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 9.47 | 13.91 | 4.71 | 5.14 | 3.20 | 2.93 | 2.40 | 5.45 | 7.65 | 12.16 | 18.36 | 1379.50 | 1079.30 | 596.20 | 1660.03 | — | — | — | — | — | — |
| — | +375.0% | +96.5% | -5.7% | -58.2% | -75.9% | -86.9% | -99.6% | -99.3% | -98.0% | -98.9% | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.11 | 8.31 | 2.54 | 2.04 | 1.59 | 1.12 | 0.82 | 1.40 | 3.18 | 3.68 | 2.97 | 5.80 | 3.56 | 1.66 | 2.73 | 1.96 | 2.11 | 3.84 | 3.67 | 4.74 | 4.82 |
| — | +639.2% | +208.9% | +45.4% | -49.9% | -69.4% | -72.3% | -75.9% | -10.8% | +121.9% | +8.8% | +196.3% | +68.9% | -56.8% | -25.6% | -58.7% | -56.3% | -30.1% | -31.7% | -34.2% | -53.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 34.3% | 60.5% | 56.1% | 40.5% | 50.3% | 43.0% | 18.5% | 13.4% | 38.2% | 32.0% | -0.8% | -915.5% | -805.6% | -825.4% | -761.3% | — | — | — | — | — | — |
| — | +40.7% | +203.8% | +202.3% | +31.7% | +34.3% | +2292.4% | +101.5% | +104.7% | +103.9% | +99.9% | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -151.1% | -19.7% | -52.3% | -113.5% | -84.7% | -133.1% | -189.8% | -245.8% | -117.5% | -152.1% | -327.6% | -16464.6% | -25156.8% | -25236.9% | -46254.6% | — | — | — | — | — | — |
| — | +85.2% | +72.5% | +53.8% | +27.9% | +12.5% | +42.1% | +98.5% | +99.5% | +99.4% | +99.3% | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -148.4% | -18.3% | -47.6% | -110.7% | -82.9% | -135.3% | -186.2% | -235.5% | -106.6% | -142.7% | -312.2% | -15800.8% | -24145.0% | -24255.9% | -44759.7% | — | — | — | — | — | — |
| — | +86.4% | +74.4% | +53.0% | +22.3% | +5.2% | +40.3% | +98.5% | +99.6% | +99.4% | +99.3% | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -55.5% | -2.9% | -6.5% | -11.1% | -10.3% | -13.0% | -15.2% | -15.7% | -10.6% | -10.8% | -13.4% | -17.9% | -18.5% | -18.2% | -17.1% | -18.4% | -23.6% | -23.0% | -19.4% | -15.6% | -15.1% |
| — | +77.9% | +57.4% | +29.2% | +3.0% | -20.2% | -13.6% | +12.0% | +42.7% | +40.3% | +21.6% | +2.9% | +21.6% | +21.0% | +11.8% | -17.9% | -56.7% | -92.6% | -65.9% | -34.9% | -50.5% | |
| ROA | -42.9% | -2.3% | -5.1% | -8.6% | -7.9% | -10.1% | -11.9% | -12.4% | -8.3% | -8.5% | -10.6% | -13.7% | -14.3% | -14.1% | -13.5% | -14.4% | -17.4% | -17.2% | -15.1% | -12.4% | -12.4% |
| — | +76.8% | +56.9% | +30.5% | +4.3% | -17.9% | -12.5% | +9.6% | +42.0% | +39.6% | +21.4% | +5.1% | +18.1% | +17.9% | +11.1% | -16.4% | -40.8% | -68.1% | -49.2% | -24.7% | -40.2% | |
| ROIC | -48.3% | -2.4% | -6.3% | -10.5% | -9.3% | -11.1% | -13.4% | -14.0% | -9.7% | -10.2% | -12.2% | -15.0% | -17.6% | -19.4% | -26.0% | -29.7% | -22.7% | -18.8% | -15.2% | -11.9% | -11.2% |
| — | +77.9% | +53.5% | +24.7% | +3.6% | -8.6% | -10.1% | +7.1% | +45.1% | +47.4% | +53.0% | +49.4% | +22.1% | -3.1% | -70.9% | -149.2% | -101.5% | -107.4% | -59.7% | -27.2% | -41.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.08 | 0.07 | 0.08 | 0.10 | 0.11 | 0.12 | 0.13 | 0.12 | 0.14 | 0.12 | 0.17 | 0.20 | 0.17 | 0.14 | 0.12 |
| — | -25.6% | -17.9% | -5.4% | -15.4% | -26.8% | -28.4% | -43.6% | -36.8% | -13.4% | -23.8% | -0.6% | -24.1% | -42.0% | -18.1% | -13.8% | +48.6% | +96.4% | +142.5% | +73.5% | +46.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.20 | 5.20 | 4.35 | 3.60 | 3.20 | 3.41 | 3.27 | 4.18 | 3.74 | 4.22 | 5.15 | 4.63 | 2.79 | 4.21 | 3.10 | 7.31 | 5.24 | 4.67 | 6.72 | 6.36 | 5.69 |
| — | +52.3% | +32.8% | -13.7% | -14.3% | -19.2% | -36.5% | -9.8% | +33.9% | +0.4% | +66.1% | -36.6% | -46.7% | -9.9% | -53.9% | +15.0% | -8.0% | -48.1% | -38.9% | -42.2% | -50.9% | |
| Quick Ratio | 2.83 | 4.67 | 3.82 | 3.15 | 2.83 | 3.00 | 2.89 | 3.64 | 3.31 | 3.90 | 4.85 | 4.42 | 2.70 | 4.11 | 2.99 | 7.31 | 5.24 | 4.67 | 6.72 | 6.36 | 5.69 |
| — | +55.8% | +32.6% | -13.5% | -14.7% | -23.0% | -40.5% | -17.6% | +22.9% | -5.1% | +62.2% | -39.5% | -48.5% | -12.0% | -55.5% | +15.0% | -8.0% | -48.1% | -38.9% | -42.2% | -50.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IOVA stock.
Iovance Biotherapeutics, Inc.'s current P/E is -16.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Iovance Biotherapeutics, Inc.'s current operating margin is -151.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Iovance Biotherapeutics, Inc.'s business trajectory between earnings reports.